ANN ARBOR, Mich., Oct. 1 /PRNewswire/ -- Assay Designs, Inc., a leading provider of immunoassay kits, antibodies, and reagents to the life sciences and translational research markets, announced two key additions to its senior leadership team:
- Michael Mullenix, PhD, has joined the company as Vice President,
Research and Development. Dr. Mullenix comes to Assay Designs from
Amgen in Thousand Oaks, CA, where he was a Principal Scientist in their
Clinical Immunology group, responsible for a team of scientists
dedicated to the development of GLP compliant immunoassays for
preclinical and clinical trials. Prior to joining Amgen, Dr. Mullenix
held a series of R&D leadership positions with Molecular Staging,
Becton Dickinson, and Strategic Diagnostics.
- Gabriella Szekely-Klepser, PhD, joined Assay Designs as Vice President,
Science and Technology. Dr. Szekely-Klepser was previously an Associate
Research Fellow at Pfizer Global R&D in Ann Arbor, where she was most
recently leader of the Translational Research Biomarker Implementation
and Biologics Bioanalytical Groups. Prior to her six years at Pfizer,
Dr. Szekely-Klepser held various R&D positions at 3M Corporation.
"We are thrilled at having Mike and Gabriella join Assay Designs,"
stated Dan Calvo, President and CEO. "Mike has a unique blend of assay
development experience from Amgen, coupled with an extensive track record
of launching innovative immunoassay kit and reagent products earlier in his
career. He knows how to drive an innovative and productive R&D pipeline
from concept to launch. Gabriella led the establishment and expansion of
Pfizer's biomarker programs across many of its therapeutic areas. She also
worked closely with several key CROs to translate and scale-up complex
assays. Her experience in developing and validating biomarker assays, and
her understanding of the critic
|SOURCE Assay Designs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved